Holen Sie sich die Stockscreener-App
19.57
125.40%
10.89
Schlusskurs vom Vortag:
$8.68
Offen:
$19.585
24-Stunden-Volumen:
52.91M
Relative Volume:
41.45
Marktkapitalisierung:
$1.22B
Einnahmen:
$840.00K
Nettoeinkommen (Verlust:
$-75.20M
KGV:
-12.29
EPS:
-1.5921
Netto-Cashflow:
$-65.69M
1W Leistung:
+98.43%
1M Leistung:
+56.52%
6M Leistung:
+157.43%
1J Leistung:
+196.89%
1-Tages-Spanne:
$19.56
$19.61
1-Wochen-Bereich:
$8.66
$9.565
52-Wochen-Spanne:
$4.19
$19.61
Silence Therapeutics Plc Adr Stock (SLN) Company Profile
Firmenname
Silence Therapeutics Plc Adr
Sektor
Branche
Telefon
44-0-20-3457 6900
Adresse
12 HAMMERSMITH GROVE, LONDON
Compare SLN vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLN
Silence Therapeutics Plc Adr
|
19.57 | 1.22B | 840.00K | -75.20M | -65.69M | -1.5921 |
VRTX
Vertex Pharmaceuticals Inc
|
500.39 | 126.83B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.59 | 90.06B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
783.39 | 80.65B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
821.21 | 51.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
370.09 | 41.87B | 5.76B | 514.49M | 1.10B | 4.4813 |
Silence Therapeutics Plc Adr Stock (SLN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-06-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-02-11 | Eingeleitet | Goldman | Sell |
| 2024-12-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2024-09-03 | Eingeleitet | Jefferies | Buy |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Outperform |
Silence Therapeutics Plc Adr Aktie (SLN) Neueste Nachrichten
Silence Therapeutics (SLN) Upgraded to Buy: Here's Why - Zacks Investment Research
Silence Therapeutics at Cantor healthcare conference: divesiran advances By Investing.com - Investing.com South Africa
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Silence (SLN) Latest Quarter: The Report Provides a New Financial Snapshot for the Current Session; Investor Response: The Stock Gains 0.76% in Latest TradingEarnings Risk Report - dars.gov.et
Silence Therapeutics (NASDAQ:SLN) Sees Strong Trading VolumeShould You Buy? - MarketBeat
What is HC Wainwright's Estimate for SLN Q3 Earnings? - MarketBeat
Silence (SLN) Earnings Numbers in Focus: The Company Reports Its Latest Available Figures for the Current Session; Price Action: Shares Close 1.74% Lower in the Current UpdateEarnings Expansion Phase - careplusvn.com
Silence (SLN) Earnings Numbers in Focus: The Company Reports Its Latest Available Figures for the Current Session; Price Action: Shares Close 1.74% Lower in the Current UpdateRevenue Guidance Range - dars.gov.et
Silence (SLN) Earnings Numbers in Focus: The Company Reports Its Latest Available Figures for the Current Session; Price Action: Shares Close 1.74% Lower in the Current UpdateTech Earnings Analysis - dars.gov.et
Silence (SLN) Earnings Numbers in Focus: The Company Reports Its Latest Available Figures for the Current Session; Price Action: Shares Close 1.74% Lower in the Current UpdateEstimate Revision Count - dars.gov.et
Silence (SLN) Earnings Numbers in Focus: The Company Reports Its Latest Available Figures for the Current Session; Price Action: Shares Close 1.74% Lower in the Current UpdateEarnings Outlook Update - https://www.dars.gov.et/
Investors Buy High Volume of Silence Therapeutics Call Options (NASDAQ:SLN) - MarketBeat
Silence Therapeutics closes $201.3M public offering By Investing.com - Investing.com South Africa
Silence Therapeutics closes $201.3M public offering - Investing.com
Silence Therapeutics closes $201.3M public offering By Investing.com - Investing.com India
Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs - Business Wire
Silence Therapeutics Director Richard Ian Griffiths Reports Multiple ADS Sales on August 10, 2026 - Kalkine Media
Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know - Yahoo Finance
Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know - Zacks Investment Research
Form 4: Griffiths Richard Ian reports acquisition/exercise transactions in SLN - Stock Titan
SLN Q2 2026 Earnings: Net Loss of $0.26 per Share Highlights Ongoing Clinical-Stage InvestmentCore Business Growth - dars.gov.et
SLN Q2 2026 Earnings: Net Loss of $0.26 per Share Highlights Ongoing Clinical-Stage InvestmentProfit Growth Outlook - dars.gov.et
SLN Q2 2026 Earnings: Net Loss of $0.26 per Share Highlights Ongoing Clinical-Stage InvestmentMargin Expansion Trends - careplusvn.com
SLN Q2 2026 Earnings: Net Loss of $0.26 per Share Highlights Ongoing Clinical-Stage InvestmentEarnings Forecast Report - dars.gov.et
SLN Q2 2026 Earnings: Net Loss of $0.26 per Share Highlights Ongoing Clinical-Stage InvestmentRevenue Estimate Trend - dars.gov.et
Silence Therapeutics Announces Pricing of $13.50 Per ADS in Public Offering - Kalkine Media
Form 8K Silence Therapeutics plc For: 12 August By Investing.com - Investing.com India
Silence Therapeutics (NASDAQ:SLN) Shares Down 6.9%What's Next? - MarketBeat
Silence Therapeutics prices $175M public offering at $13.50 per ADS - Investing.com
Why Avalon Holdings Shares Are Trading Higher By More Than 10%; Here Are 20 Stocks Moving Premarket - Sahm
Silence Therapeutics (NASDAQ:SLN) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial - sharewise.com
Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial - Yahoo Finance
Silence Therapeutics Jumps Over 25% After Divesiran Phase 2 Trial Supports 12-Week Dosing - TechStock²
Silence Therapeutics launches $150 million public offering - Investing.com
Silence Therapeutics launches $150 million public offering By Investing.com - Investing.com India
Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares - Business Wire
Silence Therapeutics (NASDAQ:SLN) Shares Gap UpStill a Buy? - MarketBeat
Silence Therapeutics Reports Q2 2026 Financial Results in SEC Filing - Kalkine Media
Silence Therapeutics Announces Positive Phase 2 SANRECO Trial Outcomes for Divesiran in Polycythemia Vera - Kalkine Media
Silence Therapeutics SLN Stock Heats Up Ahead Phase 2 Data - StocksToTrade
Silence Therapeutics (SLN) Rallies Ahead Of Key Phase 2 Data - timothysykes.com
Silence Therapeutics reports positive phase 2 trial results - Investing.com
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile - Finviz
Why is Silence Therapeutics stock surging today? By Investing.com - Investing.com South Africa
SLN Q4 2024 Earnings: Reports Positive EPS of $0.213138; Shares Move 1.96Profit Growth Outlook - careplusvn.com
SLN Q4 2024 Earnings: Reports Positive EPS of $0.213138; Shares Move 1.96Estimate Dispersion - dars.gov.et
Silence Therapeutics (NASDAQ:SLN) Reaches New 1-Year HighStill a Buy? - MarketBeat
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
SLN Q4 2024 Earnings: EPS of $0.2131 Reported; Shares Decline 9.72Tech Earnings Analysis - vinanet.vn
Finanzdaten der Silence Therapeutics Plc Adr-Aktie (SLN)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.97%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):